Telix Pharmaceuticals’ (TLX) “Outperform” Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Telix Pharmaceuticals (NASDAQ:TLX) in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a $22.00 target price on the stock.

TLX has been the subject of several other reports. Royal Bank Of Canada cut shares of Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Tuesday, July 7th. Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $20.40.

Telix Pharmaceuticals Stock Down 8.8%

NASDAQ TLX opened at $11.33 on Thursday. Telix Pharmaceuticals has a 12 month low of $6.28 and a 12 month high of $12.60. The company’s 50-day moving average price is $10.96 and its 200-day moving average price is $9.65. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Institutional Trading of Telix Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers grew its holdings in Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after acquiring an additional 1,392 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after purchasing an additional 8,423 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Telix Pharmaceuticals in the 4th quarter valued at about $89,000. XY Capital Ltd purchased a new stake in shares of Telix Pharmaceuticals in the 1st quarter worth approximately $120,000. Finally, IHT Wealth Management LLC purchased a new stake in shares of Telix Pharmaceuticals in the 2nd quarter worth approximately $213,000.

Key Headlines Impacting Telix Pharmaceuticals

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Telix reported first-half revenue of approximately $477 million, up 22% year over year, while adjusted EBITDA surged 146%. Precision Medicine revenue increased 27%, supported by higher sales of Illuccix and Gozellix. Telix 2026 Half-Year Results
• Positive Sentiment: The company is continuing to invest heavily in growth, including $124 million in research and development, while advancing late-stage prostate, kidney and brain cancer programs. Manufacturing revenue also reached $146 million as Telix expanded its global production footprint. Telix EBITDA and Revenue Report
• Positive Sentiment: Wedbush reaffirmed its “outperform” rating and assigned a $22 price target, implying substantial upside based on the cited reference price. Wedbush rating report
• Neutral Sentiment: Telix’s quarterly earnings per share exceeded consensus estimates, with reported EPS of $0.05 versus $0.04 expected. However, the reported quarterly revenue figure was below the cited analyst estimate, creating some uncertainty around how investors are interpreting the results. Telix earnings report
• Negative Sentiment: A recent analyst downgrade appears to be weighing on sentiment, likely reflecting concerns about valuation, expectations or near-term execution despite the company’s strong results. The downgrade is pressuring the stock after its recent advance. Why Telix shares were downgraded

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.